98results about How to "Inhibit proliferation" patented technology

A nucleic acid is provided which encodes a humanized antibody or fragment thereof, which encodes a protein which binds to human EGF-receptor. Monoclonal antibody 225 is the complementary determining region (CDR) donor.

The instant invention provides soluble fusion protein complexes and IL-15 variants that have therapeutic and diagnostic use, and methods for making thesuch proteins. The instant invention additionally provides methods of stimulating or suppressing immune responses in a mammal using the fusion protein complexes and IL-15 variants of the invention.

A compound represented by the following general formula (I): (I) wherein R7 and R21 are the same or different and each represents optionally substituted C2-22 alkoxy, etc.; a pharmaceutically acceptable salt thereof or hydrates of the same. The compound (1) inhibits angiogenesis and inhibits the production of VEGF particularly under hypoxic conditions, which makes it useful as a remedy for solid cancer.

The present invention provides a single-stranded circular RNA and DNA, and a preparation method and application thereof, the single-stranded circular RNA and DNA can adsorb a single-stranded circularRNA or a single-stranded circular DNA of miRNA, thereby overcoming the disadvantage that a traditional single-stranded RNA is easily degraded and has low efficiency, and can release tumor suppressor gene ''co-silencing'' caused by the miRNA. The single-stranded circular RNA or DNA prepared by the method can specifically adsorb the target miRNA so as to inhibit the proliferation, migration and invasion of tumor cells and promote the apoptosis of the tumor cells, can regulate the proportion of immune cells, has good anti-tumor and immune regulation effects, and is expected to be developed as a therapeutic drug for tumors or immune diseases.

The present invention relates to a method of making a powder from apple peel by providing an apple peel, subjecting the apple peel to a phytochemical preservation treatment, drying the treated apple peel, and grinding the dried, treated apple peel to a powder. A powder from apple peel having a phenolic content and a flavonoid content similar to fresh apple peel on a fresh weight basis, where the powder has a water activity of less than 0.30 is also disclosed. The present invention also relates to a method of treating cancer in a patient by administering a powder from apple peel to a patient under conditions effective to treat cancer. Also disclosed is a method of inhibiting proliferation of cancer cells by contacting cancer cells with a powder from apple peel under conditions effective to inhibit proliferation of the cancer cells.

The present invention discloses anti-PD-L / PD-1 Axis antibody conjugates for targeted immunotherapy, as well as compositions comprising said conjugates. Further, the present invention discloses the use of the conjugates in the treatment of tumor / cancer.

The present invention relates to compositions and methods for controlling nematode infestation of plants. In particular, the present invention provides vectors comprising sequences designed to control nematodes by RNA interference (RNAi) and transgenic plants transformed with such vectors.

The present invention relates to a novel class of fluorinated arylamide derivatives. The instant compounds can be used to treat cancer. The fluorinated arylamide derivatives can also inhibit histone deacetylase and are suitable for use in selectively inducing terminal differentiation, and arresting cell growth and / or apoptosis of neoplastic cells, thereby inhibiting proliferation of such cells. Thus, the compounds of the present invention are useful in treating a patient having a tumor characterized by proliferation of neoplastic cells. The compounds of the invention may also be useful in the prevention and treatment of TRX-mediated diseases, such as autoimmune, allergic and inflammatory diseases, and in the prevention and / or treatment of diseases of the central nervous system (CNS), such as neurodegenerative diseases. The present invention further provides pharmaceutical compositions comprising the hydroxamic acid derivatives and safe dosing regimens of these pharmaceutical compositions, which are easy to follow, and which result in a therapeutically effective amount of the hydroxamic acid derivatives in vivo.

The inhibitory RNA for inhibiting the expression of ZFAT gene according to this invention is a siRNA comprising a sense RNA having a base sequence of contiguous 20 to 20 bases, preferably 23 to 27 bases, of ZFAT mRNA and an anti-sense RNA having a base sequence complementary to the base sequence of the sense RNA or a shRNA comprising a double-stranded RNA (dsRNA) with the sense RNA connected to the anti-sense RNA via a loop sequence.The inhibitory RNA for inhibiting the expression of ZFAT gene according to this invention decreases a rate of cell proliferation of cancer cells, etc., induces apoptosis of cells including cancer cells, or inhibits an immunoresponse by inhibiting the expression of the ZFAT gene. Therefore, the inhibitory RNA of this invention is useful for development of molecular target agents particularly for cancer cells or immunosuppressive agents.

A compound of formula (I) or (II) and use of the compound in the preparation of drugs for treating cancer are disclosed. The study shows that the compounds can inhibit the growth of many kinds of tumor cells, can be used for targeting epidermal growth factor receptor (EGFR), and particularly can inhibit tumor cells with single or multiple mutations of EGFR (T790M). Therefore, the compound can be used as EGFR inhibitor to treat cancer and has a relatively large application value.

The invention relates to the biological medicine field, and concretely relates to an application of DHM in the preparation of anti-hepatoma medicines. The DHM has a strong anticancer characteristic as a flavonoid compound. Tests prove that the DHM plays a positive role in hepatoma carcinoma cell propagation inhibition, hepatoma carcinoma cell apoptosis induction, hepatoma carcinoma cell adhesion capability reduction and hepatoma carcinoma cell invasion and transfer prevention, and can substantially reduce the contents of peroxides, glutathione and ATP in the hepatoma carcinoma cells.

The invention relates to bacillus velezensis YGA1 as well as a preparation method and application thereof, and belongs to the technical field of microbe application. The bacillus velezensis YGA1 bacterial stain is preserved in CCTCC (China Center for Type Culture Collection) on November 17, 2017, and has the preservation code being CCTCC M 2017705. When the addition of the concentration fermentation liquid prepared from the YGA1 stain is 0.1 to 1.0 percent, the sensory quality of the material liquid can be effectively stabilized; the proliferation of decay bacteria in the material liquid is inhibited; the expiration date of the material liquid is prolonged; the cigarette sensory evaluation smoking effect shows that the addition quantity does not have influence on the cigarette sensory smoking quality. The method has the advantages that the cost is low; the implementation of the operation method is easy; great application potential is realized in aspects of prolonging the expiration date of the material liquid and preventing the material liquid deterioration.

The invention relates to application of formononetin in preparing of a medicament for restricting angiogenesis. The invention has the advantages that: the new application of the formononetin is provided, the fact that the formononetin can effectively restrict the propagation and the migration of endothelial cells in veins and canaliculization is found first, and firstly found in the invention, the formononetin has an anti-angiogenesis activity and can be used as an angiogenesis depressor. The invention firstly finds that the formononetin has the anti-angiogenesis action and can be applied to the preparation of the angiogenesis medicament as an angiogenesis depressor so as to treat angiogenesis-dependent and angiogenesis-associated diseases, such as tumors, arthritis, psoriasis, eye diseases, atherosclerosis, and the like.

The invention discloses a combined antitumor drug. The combined antitumor drug comprises an antiangiogenic drug, a drug used for inhibiting tumor cell proliferation, and an amphiphilic high molecular material; the antiangiogenic drug is a prodrug of Combretastatin A4, and the drug used for inhibiting tumor cell proliferation is a camptothecin antitumor drug. The invention also discloses a combined antitumor drug nanoparticle preparation, a preparation method, and applications. It is shown by cytotoxicity test that the combined antitumor drug nanoparticle preparation is capable of inhibiting proliferation of tumour cell HT-29 and human umbilical vein vascular endothelial cells (HUVEC) obviously, and dose-dependent relationship is detected; it is confirmed by scratch injury experiments and lumen formation experiments that the combined antitumor drug nanoparticle preparation is capable of inhibiting migration of HUVEC and vascularization; compared with single medication systems, the combined antitumor drug nanoparticle preparation possesses excellent tumor killing effect in vivo, clinical application value is high, and application prospect is promising.

The present invention discloses a class of 4-pyrimidinediamine small molecule organic compounds or related analogs or pharmaceutically acceptable salts thereof, wherein the structure is represented byformulas (I)-(VI). The present invention further discloses uses of the 4-pyrimidinediamine small molecule organic compounds or a pharmaceutical composition thereof in preparation of drugs for preventing and / or treating various malignant tumors, autoimmune diseases, inflammation and the like, and uses as B cell lymphokine 6 (BCL6) inhibitors in preparation of drugs for preventing and / or treating BCL6 mediated diseases.

The invention provides a cobalt-base alloy. The cobalt-base alloy comprises a Cu element, and the content of the Cu element is 4.5-5.5 percent by weight. The invention further provides a thermal processing method and a thermal treatment method of the cobalt-base alloy, as well as an application of the cobalt-base alloy as a coronary stent. The cobalt-base alloy can be used for persistently generating trace copper in the cardiovascular system, and is capable of inhibiting hyperplasia, migration and degeneration of artery smooth muscles caused after the coronary stent is implanted and effectively reducing formation of thrombus, so that the function of reducing or inhibiting in-stent restenosis caused after the coronary stent is implanted is realized.

The present disclosure relates to a HLA-G specific chimeric antigen receptor, a nucleic acid, a HLA-G specific chimeric antigen receptor expression plasmid, a HLA-G specific chimeric antigen receptor expressing cell, a pharmaceutical composition for treating cancer, and use of the HLA-G specific chimeric antigen receptor expressing cell. The chimeric antigen receptor specifically binds to human leukocyte antigen G. The nucleic acid encodes the HLA-G specific chimeric antigen receptor. The HLA-G specific chimeric antigen receptor expression plasmid expresses the HLA-G specific chimeric antigen receptor. The HLA-G specific chimeric antigen receptor expressing cell is obtained by transducing the HLA-G specific chimeric antigen receptor into an immune cell. The pharmaceutical composition for treating cancer includes the HLA-G specific chimeric antigen receptor expressing cell and a pharmaceutically acceptable carrier.

The invention discloses a recombinant mesenchymal stem cell, and a preparation method and application thereof. The recombinant mesenchymal stem cell is obtained by modifying mesenchymal stem cells bychemokine genes, can convert non-immunogenic tumors into immunogenic tumors, and can be combined with a PD1 antibody to inhibit proliferation of solid tumors, and the content of infiltrating lymphocytes in the tumors is obviously increased. The preparation method of the recombinant mesenchymal stem cells has the advantages of simple operation, easy control of conditions and low cost, and is suitable for large-scale application.

The invention discloses an antimicrobial peptide. A gene sequence of the antimicrobial peptide is shown as sequence table SEQ ID No.1; an amino acid sequence of the antimicrobial peptide is shown as sequence table SEQ ID No.2; a mature polypeptide sequence of the antimicrobial peptide is shown as sequence table SEQ ID No.3. By identifying the antimicrobial peptide from armyworm body and performingin vitro chemical synthesis, the invention finds that the in vitro prepared antimicrobial peptide Cecropin has an excellent antibacterial effect to escherichia coli; a basis is established for developing an antibiotic substitute for treating escherichia coli, so that the pollution to animal by-products and environment caused by the usage of mass antibiotics can be reduced.

The invention belongs to the field of nanomedicine and biomedicine, and discloses a preparation method and application of highly nucleus-targeted anti-tumor nanomedicine. According to the preparationmethod and the application of the highly nucleus-targeted anti-tumor nanomedicine, a polypeptide with nucleus targeting ability and graphite powder are subjected to blending and ball milling, and polypeptide functionalized graphene (TG) with high tumor targeting ability and nucleus targeting ability is prepared under normal temperature and pressure. Furthermore, carboxyl group is introduced into the TG by using an acetic acid plasma technology, and the anti-tumor drug mitomycin C (MMC) is loaded on the TG. The prepared anti-tumor nanomedicine MMC-TG has good tumor cell nucleus targeting ability and can highly selectively target tumor cells. The tumor killing rate is 95% or above, but at the same time, the anti-tumor nanomedicine MMC-TG has little damage to normal cells. Experimental results confirm that the developed nanomedicine first plays a role in the nucleus, and has efficient tumor cell nucleus targeting ability, tumor killing ability and tumor metastasis inhibiting ability.

The invention relates to Chinese medicine used for treating chronic kidney disease, especially for treating kidney inflammation, invisible kidney inflammation and nephritic syndrome, and a preparation method of the Chinese medicine. The medicine is made of yerbadetajo, Ligustrum lucidum, Leonurus japonicus, Salvia, Rehmanniae, Lonicera confuse, Madder, Lycium Chinese Mill and Scorpion. The medicine has the efficacy of replenishing vital essence, tonifying kidney-yin, activating blood and dissolving stasis. The medicine is mainly applicable to treating kidney deficiency as well as the chronic kidney disease, the invisible kidney inflammation and the nephritic syndrome and also can be used for treating the nephritic syndrome in conjunction with western medicine such as Glucocorticoid. The medicine can improve curative effect, put off recurrence and reduce the times of recurrence. The medicine of the invention can be made into any formulation which is suitable for clinical treatment, including powders, decoction, mixture, oral liquor, capsule, granular formulation and a condensed pill and so on.

The invention provides a plasmid for treating 1 type diabetes, which is a double-gene eukaryon co-expression plasmid built by a gene recombination method and containing a pancreas islet beta cell regeneration (Reg) III gene and a proinsulin gene, wherein the Reg III gene and the proinsulin gene can be respectively expressed under the induction of an EF-1alpha promoter and a cytomegalovirus (CMV) promoter of a pBudCE4.1 plasmid vector. The Reg III / proinsulin double-gene eukaryon co-expression plasmid can play a hypoglycemic role by recovering the autoimmunity tolerance state of in the body of a 1 type diabetes patient and promoting the regeneration of beta cells.

Novel quinone and catechol compositions, compositions containing prodrugs of quinone and catechol compositions, and methods of use for the treatment of solid tumor cancers and other vascular proliferative disorders. The disclosure particularly relates to the discovery of dual activity agents capable of generating both a vascular targeting effect and direct tumor cell cytotoxicity in order to achieve an enhanced anti-tumor response in a patient.

The invention provides a screening method for benign lactobacillus strain capable of reducing the secondary precipitation of soybean sauce. The method includes the following steps: S1, performing amplification culture on different sets of lactobacilli, performing microscopic examination on a nutrient solution, and preliminarily screening strains with 3-8 cells connected together; S2, performing salt tolerance analysis test on the lactobacillus strains preliminarily screened in the S1, and secondarily screening the lactobacilli suitable for high salt soy sauce brewing process; and S3, adding the lactobacilli through secondary screening in the S2 into soy sauce mash to perform fermentation, detecting histamine and tyramine content in supernatant after the fermentation is completed, selectingthe lactobacilli whose histamine and tyramine content are lower than 25 mg / L, which are the required lactobacillus strains. A soybean sauce preparation technology applying the screened benign lactobacillus strains is simultaneously provided. The benign lactobacilli can be obtained through strain forms, salt tolerance test and soy sauce mash fermentation and screening and added at a soy sauce mashpreparation phase, so that the secondary precipitation of soybean sauce can be reduced, and the flavor of the soybean sauce can be improved.

The invention provides compositions containing an effective amount of a therapeutic agent encapsulated in a liposome coupled to a desialyated glycoprotein, e.g., desialyated glycoprotein-α1. This invention further provides methods for the targeted delivery of a therapeutic agent to a tissue expressing asialoglycoprotein receptors by delivery to the tissue an effective amount of a composition containing an effective amount of the agent encapsulated in a liposome coupled to a desialyated glycoprotein, e.g., desialyated glycoprotein-α1. Also provided by this invention is a method for inhibiting the proliferation of liver cancer by administering to a subject in need of such therapy an effective amount of a composition containing doxorubicin encapsulated in desialyated glycoprotein-α1 coupled to a liposome.

The invention belongs to the gene engineering and chemical field and relates to application of FD4: N-(3-(benzamide)-5-(4-oxo-4H-3,1-benzoxazine-2-yl) phenyl) benzamide to preparing an antitumor drug. The FD4 can obviously inhibit proliferation of tumor cells, is a drug designed aiming to a cell target CYPJ (Cyclophilin J), is not easy to cause the drug resistance and also has special and obvious effect to the tumor cells of a high expression CYPJ protein. Therefore, a small molecular compound is developed as a novel antitumor drug and has obvious tumor killing effect and good specificity, and the FD4 can be developed as the novel antitumor drug and provides a new way and means to treat and cure the tumor.

The invention discloses a hollow capsule adopting lactobacillus acidophilus. The hollow capsule is prepared from the following components in parts by mass: 5-10 parts of lactobacillus acidophilus powder, 30-40 parts of enzyme-method bone gelatin, 5-15 parts of seaweed gel, 10-20 parts of calcium alginate, 10-18 parts of hydroxypropyl methyl cellulose, 15-25 parts of ethyecellulose, 30-40 parts of ethanol, 2-6 parts of yeast extract, 2-8 parts of grape seed extract, 1-4 parts of beeswax, 2-6 parts of maltose, 1-4 parts of glycerol, 1-3 parts of sorbitol, 2-5 parts of triethyl ester, 0.5-1 part of edible pigment, 0.2-0.4 part of paraben, 0.2-0.6 part of methyl silicone oil and 70-100 parts of purified water. According to the hollow capsule, the lactobacillus acidophilus powder is added so that the intestines and stomach health function of the hollow capsule can be enhanced, and medicines can be sufficiently absorbed by the intestines and stomach.

The invention belongs to the chemical industry field and the medicine field, and relates to an application of magnolol in preparation of antitumor drugs. The invention provides the application of magnolol in preparation of antitumor drugs, and the tumor cells comprise liver cancer cells, and cervical cancer cells. The magnolol belongs to a natural product, has little toxic and side effect, high bioavailability, and stable properties, and has clinical application value. The micromolecular compound of the invention can be developed as a new antitumor drug or its auxiliary component, has obvious tumor suppression effect, is green and environment-friendly, and provides a new approach and means for treating and curing tumors.

The invention includes compositions and methods for inhibiting proliferation and inducing apoptosis in activated lymphocytes, treating diseases associated with activated lymphocytes, or treating PAH.